Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue , 2013, Pages 185-192

  Kreutz, Rolf P ^a,b   Owens, Janelle ^b   Jin, Yan ^b   Nystrom, Perry ^b   Desta, Zeruesenay ^b   Kreutz, Yvonne ^b   Breall, Jeffrey A ^a   Li, Lang ^b   Chiang, Chien Wei ^b   Kovacs, Richard J ^a   Flockhart, David A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clopidogrel; CYP450; Pharmacogenetics; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYTOCHROME P450 3A4; HYPOXIA INDUCIBLE FACTOR 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; ARNT ALPHA GENE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYP3A4 GENE; DNA POLYMORPHISM; DOSE RESPONSE; FEMALE; GENE ACTIVITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACODYNAMICS; PHARMACOGENETICS; PPAR ALPHA GENE; THROMBOCYTE AGGREGATION; UPREGULATION;

EID: 84890362511     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S53151     Document Type: Article

References (33)

1. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010; 38(1): 92-99.
2. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011; 90(2): 328-332.
3. Lewis JP, Horenstein RB, Ryan K, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013; 23(1): 1-8.
4. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89(1): 65-74.
5. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011; 57(11): 1251-1263.
6. Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008; 6(8): 1439-1441.
7. Kreutz RP, Nystrom P, Kreutz Y, et al. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol. 2012; 4: 13-20.
8. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clincal efficacy of clopidogrel. JAMA. 2009; 302(8): 849-857.
9. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3 A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109(2): 166-171.
10. Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol. 2011; 57(1): 86-93.
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360(4): 354-362.
12. Frelinger AL 3rd, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013; 61(8): 872-879.
13. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002; 3(6): 561-597.
14. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013; 14(1): 47-62.
15. Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 2012; 91(6): 1044-1052.
16. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011; 11(4): 274-286.
17. Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000; 10(5): 373-388.
18. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011; 57(11): 1574-1583.
19. Elens L, Becker ML, Haufroid V, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics. 2011; 21(12): 861-866.
20. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012; 22(5): 373-380.
21. Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost. 2008; 99(1): 215-222.
22. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25): 2577-2585.
23. Kreutz RP, Tantry US, Bliden KP, Gurbel PA. Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. Blood Coagul Fibrinolysis. 2007; 18(8): 713-718.
24. Kreutz RP, Alloosh M, Mansour K, et al. Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity. Diabetes Metab Syndr Obes. 2011; 4: 99-105.
25. Kreutz RP, Breall JA, Kreutz Y, et al. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thromb Res. 2012; 130(2): 198-202.
26. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005; 46(9): 1705-1709.
27. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. The CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci. 2013; 38(3): 349-354.
28. Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008; 28(12): 1483-1494.
29. Michalik L, Wahli W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008; 2008: 134059.
30. Rakhshandehroo M, Hooiveld G, Müller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One. 2009; 4(8): e6796.
31. Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol. 2008; 48: 1-32.
32. Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-targeted pharmacogenomics of CYP1 A2 in human liver. Front Pharmacol. 2010; 1: 129.
33. Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol. 2011; 58(25): 2630-2639.